Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3,367,000
-
Total 13F shares
-
1,069,490
-
Share change
-
-2,785
-
Total reported value
-
$3,583,217
-
Price per share
-
$3.35
-
Number of holders
-
15
-
Value change
-
-$8,652
-
Number of buys
-
5
-
Number of sells
-
8
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q4 2023
As of 31 Dec 2023,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,069,490 shares.
The largest 10 holders included
Slate Path Capital LP, MFN Partners Management, LP, TYNDALL CAPITAL PARTNERS L P, FMR LLC, Artal Group S.A., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock Inc., UBS Group AG, and MORGAN STANLEY.
This page lists
15
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.